The latest price target for 4D Molecular Therapeutics (NASDAQ:FDMT) was reported by Morgan Stanley on January 13, 2025. The analyst firm set a price target for $6.00 expecting FDMT to rise to within 12 months (a possible 31.00% upside). 29 analyst firms have reported ratings in the last year.

The latest analyst rating for 4D Molecular Therapeutics (NASDAQ:FDMT) was provided by Morgan Stanley, and 4D Molecular Therapeutics maintained their underweight rating.

The last upgrade for 4D Molecular Therapeutics Inc happened on November 15, 2022 when Goldman Sachs raised their price target to $68. Goldman Sachs previously had a neutral for 4D Molecular Therapeutics Inc.

The last downgrade for 4D Molecular Therapeutics Inc happened on September 23, 2024 when Cantor Fitzgerald changed their price target from N/A to N/A for 4D Molecular Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of 4D Molecular Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for 4D Molecular Therapeutics was filed on January 13, 2025 so you should expect the next rating to be made available sometime around January 13, 2026.

While ratings are subjective and will change, the latest 4D Molecular Therapeutics (FDMT) rating was a maintained with a price target of $8.00 to $6.00. The current price 4D Molecular Therapeutics (FDMT) is trading at is $4.58, which is out of the analyst’s predicted range.